ReviewCancer metastasis reviews2024

Comprehensive assessment of TECENTRIQ® and OPDIVO®: analyzing immunotherapy indications withdrawn in triple-negative breast cancer and hepatocellular carcinoma.

Ghazaal Roozitalab et al.PubMed ↗Publisher ↗

No numbers read from the abstract.